Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
- 24 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2014 New trial record